Associated Papers
Exploring Trimethylaminuria: Genetics and Molecular Mechanisms, Epidemiology, and Emerging Therapeutic Strategies.
Sidoti A et al.
Biology, 2024
Adaptive Modelling of Mutated FMO3 Enzyme Could Unveil Unexplored Scenarios Linking Variant Haplotypes to TMAU Phenotypes.
Alibrandi S et al.
Molecules (basel, Switzerland), 2021
Survey of variants of human flavin-containing monooxygenase 3 (FMO3) and their drug oxidation activities.
Yamazaki H et al.
Biochemical Pharmacology, 2013
FMO3 allelic variants in Sicilian and Sardinian populations: trimethylaminuria and absence of fish-like body odor.
D'Angelo R et al.
Gene, 2013
Trimethylaminuria: an under-recognised and socially debilitating metabolic disorder.
Christodoulou J
Journal of Paediatrics and Child Health, 2012
A common FMO3 polymorphism may amplify the effect of nicotine exposure in sudden infant death syndrome (SIDS).
Poetsch M et al.
International Journal of Legal Medicine, 2010
Flavin-containing monooxygenase 3 and human disease.
Motika MS et al.
Expert Opinion on Drug Metabolism & Toxicology, 2007
The implications of polymorphisms in mammalian flavin-containing monooxygenases in drug discovery and development.
Cashman JR
Drug Discovery Today, 2004
Trimethylaminuria and a human FMO3 mutation database.
Hernandez D et al.
Human Mutation, 2003
Deleterious mutations in the flavin-containing monooxygenase 3 (FMO3) gene causing trimethylaminuria.
Zhang J et al.
Pharmacogenetics, 2003
Interindividual differences of human flavin-containing monooxygenase 3: genetic polymorphisms and functional variation.
Cashman JR et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals, 2002
Biochemical and molecular studies in mild flavin monooxygenase 3 deficiency.
Zschocke J et al.
Journal of Inherited Metabolic Disease, 2000
Mild trimethylaminuria caused by common variants in FMO3 gene.
Zschocke J et al.
Lancet (london, England), 1999
Select a paper to view details